title: Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
abstract: The efficacy and safety of oral placebo or odanacatib 10, 25, or 50 mg once weekly for 52 weeks were evaluated in a double-blind, randomized, multi-center study in Japanese female and male patients with osteoporosis.
  
  
  BACKGROUND
  Odanacatib is a selective and reversible cathepsin K inhibitor that decreases bone resorption and increases bone mineral density (BMD).
  
  
  METHODS
  The primary efficacy endpoint was percent change from baseline to week 52 in lumbar spine BMD. Secondary endpoints included percent change in total hip, femoral neck, and trochanter BMD and in bone biomarkers after treatment for 52 weeks.
  
  
  RESULTS
  In this study, 286 patients [94% female, mean age (SD) 68.2 (7.1) years] were included in the analysis. The least-squares mean percent changes from baseline to week 52 in the groups receiving placebo, 10, 25 and 50 mg of odanacatib for lumbar spine (L1~L4) BMD were 0.5, 4.1, 5.7, and 5.9% and for total hip BMD were -0.4, 1.3, 1.8, and 2.7%, respectively. The changes in femoral neck and trochanter BMD were similar to those at the total hip. Bone turnover markers were reduced in a dose-dependent manner. However, the effects of odanacatib on bone formation markers were less compared with the effects on bone resorption markers. Tolerability and safety profiles were similar among all treatment groups with no dose-related trends in any adverse events.
  
  
  CONCLUSIONS
  Weekly odanacatib treatment for 52 weeks increased BMD at the lumbar spine and at all hip sites in a dose-dependent manner and was well tolerated in Japanese patients with osteoporosis.
authors.affiliation: National Center for Global Health and Medicine, Shinjuku-ku Tokyo, 162-8655, Japan, toshinak@med.uoeh-u.ac.jp.
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: M
authors.initials: M
authors.lastname: Shiraki
authors.forename: M
authors.initials: M
authors.lastname: Fukunaga
authors.forename: T
authors.initials: T
authors.lastname: Tomomitsu
authors.forename: A C
authors.initials: AC
authors.lastname: Santora
authors.forename: R
authors.initials: R
authors.lastname: Tsai
authors.forename: G
authors.initials: G
authors.lastname: Fujimoto
authors.forename: M
authors.initials: M
authors.lastname: Nakagomi
authors.forename: H
authors.initials: H
authors.lastname: Tsubouchi
authors.forename: E
authors.initials: E
authors.lastname: Rosenberg
authors.forename: S
authors.initials: S
authors.lastname: Uchida
mesh_terms: D000368:Aged; D000886:Anthropometry / Q000379:methods; D015415:Biomarkers / Q000097:blood; D001713:Biphenyl Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D056657:Cathepsin K / Q000037:antagonists & inhibitors*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006621:Hip Joint / Q000503:physiopathology; D006801:Humans; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000503:physiopathology; D058866:Osteoporotic Fractures / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D001713:Biphenyl Compounds; D050071:Bone Density Conservation Agents; D056657:Cathepsin K; C527128:odanacatib